Humana (NYSE:HUM) Price Target Raised to $521.00

Humana (NYSE:HUM) had its target price upped by Guggenheim from $471.00 to $521.00 in a report released on Monday morning,Benzinga reports. Guggenheim currently has a buy rating on the insurance provider’s stock.

Several other analysts have also commented on HUM. JPMorgan Chase & Co. increased their price target on shares of Humana from $316.00 to $393.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Raymond James Financial reissued an “outperform” rating on shares of Humana in a research report on Friday, November 6th. Barclays raised their target price on shares of Humana from $515.00 to $582.00 and gave the company an “overweight” rating in a research note on Friday, October 9th. Zacks Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Citigroup initiated coverage on Humana in a research report on Friday, October 9th. They set a “buy” rating on the stock. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $472.17.

Humana Stock Performance

Shares of NYSE:HUM opened at $446.33 on Monday. The company has a market capitalization of $53.60 billion, a price-to-earnings ratio of 33.04, a price-to-earnings-growth ratio of 2.30 and a beta of 0.65. Humana has a 52 week low of $163.11 and a 52 week high of $456.50. The company has a quick ratio of 1.74, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. The firm has a 50 day moving average of $406.79 and a 200 day moving average of $314.80.

Humana (NYSE:HUM) last posted its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The company had revenue of $41.16 billion during the quarter, compared to analyst estimates of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. Humana’s revenue was up 26.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. On average, sell-side analysts predict that Humana will post 9.56 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s dividend payout ratio is presently 34.44%.

Institutional Trading of Humana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Johnson Financial Group Inc. purchased a new stake in Humana during the 2nd quarter valued at about $26,000. Trust Co. of Vermont acquired a new position in shares of Humana in the second quarter valued at about $28,000. Bogart Wealth LLC raised its stake in shares of Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock worth $29,000 after purchasing an additional 48 shares during the last quarter. MidFirst Bank purchased a new position in shares of Humana in the second quarter worth about $35,000. Finally, Global Assets Advisory LLC purchased a new position in shares of Humana in the first quarter worth about $38,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Top Humana Stories

Here are a few of the latest stories about HUM:

• Positive Sentiment: Humana’s new oncology model, developed with Evolent and American Oncology Network, aims to reduce prior-authorization delays and administrative work while using data analytics to support value-based care. Investors may see the initiative as a way to improve care coordination and control costs. Article: New oncology model from Humana, Evolent and American Oncology Network
• Neutral Sentiment: Humana also launched cash tender offers for up to $1.5 billion of senior notes. The move signals active debt management, though its effect on the stock may depend on the terms and impact on the company’s balance sheet. Article: Humana shares gain as investors digest outlook and debt tender
• Negative Sentiment: TD Cowen’s $430 target remains below the cited share price, and its Hold rating suggests the firm sees limited near-term upside at current levels. Article: TD Cowen raises Humana price target

About Humana

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.